Filtered By:
Condition: Heart Attack
Nutrition: Vitamin A

This page shows you your search results in order of date. This is page number 2.

Order by Relevance | Date

Total 53 results found since Jan 2013.

State of target organs damage and prevalence of clinical associated conditions in patients with a hypertensive crisis and uncontrolled hypertension. (pilot study)
CONCLUSIONS: Patients with hypertensive crisis have more pronounced damage of target organs, as well as the most frequent prevalence of associated clinical conditions.PMID:36027392 | DOI:10.1097/01.hjh.0000838492.53623.dc
Source: Atherosclerosis - August 26, 2022 Category: Cardiology Authors: Tatyana Solntseva Anastasia Denisova Olga Sivakova Irina Chazova Source Type: research

State of target organs damage and prevalence of clinical associated conditions in patients with a hypertensive crisis and uncontrolled hypertension. (pilot study)
CONCLUSIONS: Patients with hypertensive crisis have more pronounced damage of target organs, as well as the most frequent prevalence of associated clinical conditions.PMID:36027392 | DOI:10.1097/01.hjh.0000838492.53623.dc
Source: Atherosclerosis - August 26, 2022 Category: Cardiology Authors: Tatyana Solntseva Anastasia Denisova Olga Sivakova Irina Chazova Source Type: research

Chronopharmacology of immune-related diseases
Allergol Int. 2022 Jul 15:S1323-8930(22)00075-2. doi: 10.1016/j.alit.2022.06.006. Online ahead of print.ABSTRACTClock genes, circadian pacemaker resides in the paired suprachiasmatic nuclei (SCN), control various circadian rhythms in many biological processes such as physiology and behavior. Clock gene regulates many diseases such as cancer, immunological dysfunction, metabolic syndrome and sleep disorders etc. Chronotherapy is especially relevant, when the risk and/or intensity of the symptoms of disease vary predicably over time as exemplified by allergic rhinitis, arthritis, asthma, myocardial infarction, congestive hea...
Source: Cancer Control - July 19, 2022 Category: Cancer & Oncology Authors: Shigehiro Ohdo Satoru Koyanagi Naoya Matsunaga Source Type: research

Sensors, Vol. 22, Pages 4310: Cardiovascular Disease Diagnosis from DXA Scan and Retinal Images Using Deep Learning
In this study, we aimed at diagnosing CVD using a novel approach integrating information from retinal images and DXA data. We considered an adult Qatari cohort of 500 participants from Qatar Biobank (QBB) with an equal number of participants from the CVD and the control groups. We designed a case-control study with a novel multi-modal (combining data from multiple modalities—DXA and retinal images)—to propose a deep learning (DL)-based technique to distinguish the CVD group from the control group. Uni-modal models based on retinal images and DXA data achieved 75.6% and 77.4% accuracy, respective...
Source: Sensors - June 7, 2022 Category: Biotechnology Authors: Hamada R. H. Al-Absi Mohammad Tariqul Islam Mahmoud Ahmed Refaee Muhammad E. H. Chowdhury Tanvir Alam Tags: Article Source Type: research

Toku Eyes launches AI retinal health scanner in the US
The AI platform can predict a person ' s risk of having a stroke or a heart attack in the next five years.
Source: mobihealthnews - June 1, 2022 Category: Information Technology Source Type: news

Association of retinal atherosclerosis assessed using Keith-Wagener-Barker system with incident heart failure and other atherosclerotic cardiovascular disease: Analysis of 319,501 individuals from the general population
CONCLUSIONS: The assessment of RA may be useful to identify people at high-risk for the development of HF and other atherosclerotic CVD events in a general population.PMID:35292151 | DOI:10.1016/j.atherosclerosis.2022.02.024
Source: Atherosclerosis - March 16, 2022 Category: Cardiology Authors: Satoshi Matsuoka Hidehiro Kaneko Akira Okada Hidetaka Itoh Yuta Suzuki Katsuhito Fujiu Nobuaki Michihata Taisuke Jo Norifumi Takeda Hiroyuki Morita Sunao Nakamura Koichi Node Hideo Yasunaga Issei Komuro Source Type: research

AlzEye: longitudinal record-level linkage of ophthalmic imaging and hospital admissions of 353 157 patients in London, UK
Purpose Retinal signatures of systemic disease (‘oculomics’) are increasingly being revealed through a combination of high-resolution ophthalmic imaging and sophisticated modelling strategies. Progress is currently limited not mainly by technical issues, but by the lack of large labelled datasets, a sine qua non for deep learning. Such data are derived from prospective epidemiological studies, in which retinal imaging is typically unimodal, cross-sectional, of modest number and relates to cohorts, which are not enriched with subpopulations of interest, such as those with systemic disease. We thus linked longitu...
Source: BMJ Open - March 16, 2022 Category: General Medicine Authors: Wagner, S. K., Hughes, F., Cortina-Borja, M., Pontikos, N., Struyven, R., Liu, X., Montgomery, H., Alexander, D. C., Topol, E., Petersen, S. E., Balaskas, K., Hindley, J., Petzold, A., Rahi, J. S., Denniston, A. K., Keane, P. A. Tags: Open access, Ophthalmology Source Type: research

Causal associations between circulating adipokines and cardiovascular disease: A Mendelian randomization study
CONCLUSIONS: Our findings reveal the causal association between resistin and AF, probably acting through blood pressure, and suggest potential causal associations between chemerin and CAD, RBP4 and HF.PMID:35134201 | DOI:10.1210/clinem/dgac048
Source: The Journal of Clinical Endocrinology and Metabolism - February 8, 2022 Category: Endocrinology Authors: Delong Chen Yuxuan Zhang Abuduwufuer Yidilisi Yi Xu Qichao Dong Jun Jiang Source Type: research

Incorporation of Retinal Arteriolosclerosis into Risk Stratification of Blood Pressure Category According to the 2017 ACC/AHA Blood Pressure Guideline
CONCLUSION: Incorporation of the assessment for RA may facilitate the CVD risk stratification of people classified based on the 2017 ACC/AHA BP guideline, particularly for those categorized in stage 1 hypertension.PMID:34866070 | DOI:10.5551/jat.63262
Source: Journal of Atherosclerosis and Thrombosis - December 6, 2021 Category: Cardiology Authors: Satoshi Matsuoka Hidehiro Kaneko Tatsuya Kamon Yuta Suzuki Yuichiro Yano Akira Okada Hidetaka Itoh Kojiro Morita Akira Fukui Katsuhito Fujiu Nobuaki Michihata Taisuke Jo Norifumi Takeda Hiroyuki Morita Sunao Nakamura Takashi Yokoo Akira Nishiyama Koichi N Source Type: research

Retinal arteriolar tortuosity and fractal dimension are associated with long-term cardiovascular outcomes in people with type 2 diabetes
Conclusions/interpretationArteriolar tortuosity and fractal dimension were associated with incident cerebrovascular events, independent of a wide range of traditional cardiovascular risk factors including diabetic retinopathy. These findings suggest potential for measurements of early retinal vasculature change to aid in the identification of people with type 2 diabetes who are at increased risk from stroke.Graphical abstract
Source: Diabetologia - September 28, 2021 Category: Endocrinology Source Type: research

FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news